nach oben

Drugs

Erschienen in:

01.04.2017 | AdisInsight Report

Sarilumab: First Global Approval

verfasst von: Lesley J. Scott

Erschienen in: Drugs | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Sarilumab (Kevzara™) is a fully human IgG1 monoclonal antibody that binds specifically to both soluble and membrane-bound interleukin (IL)-6 receptors (sIL-6Rα and mIL-6Rα) and thereby inhibits IL-6-mediated signalling through these receptors. Subcutaneous sarilumab is approved in Canada for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more biological or non-biological disease-modifying anti-rheumatic drugs. It is under regulatory review for use in rheumatoid arthritis in other countries, including in the EU, USA and Japan. Sarilumab is also under phase II investigation for the treatment of juvenile idiopathic arthritis. This article summarizes the milestones in the development of sarilumab leading to its first global approval for the treatment of rheumatoid arthritis.

Sanofi-aventis Canada Inc. Kevzara™ (sarilumab): product monograph (Canada). 2017. http://pdf.hres.ca/dpd_pm/00037766.PDF. Accessed 6 Mar 2017.

Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatois arthritis. Ther Adv Musculoskel Dis. 2010;2(5):247–56.CrossRef

Smolen JS, Aletaha D, McInnes IA. Rheumatoid arthritis. Lancet. 2016;388:23–38.

Sanofi, Regeneron Pharmaceuticals. Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab. 2016. http://www.sanofi.com. Accessed 15 Feb 2017.

Sanofi, Regeneron Pharmaceuticals Inc. Sanofi and Regeneron announce first approval of Kevzara^TM (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients by Health Canada. 2017. http://www.sanofi-aventis.com. Accessed 1 Feb 2017.

Regeneron Pharmaceuticals. Regeneron report third quarter 2016 financial and operating results. Media release. 2016. http://newsroom.regeneron.com/. Accessed 1 Feb 2017.

Sanofi, Regeneron Pharmaceuticals. Juvenile idiopathic arthritis: NCT02776735 and NCT02991469. 2017. http://clinicaltrials.gov. Accessed 15 Feb 2017.

Sanofi, Regeneron Pharmaceuticals. Ankylosing spondylitis: NCT01118728 and NCT01061723. 2017. http://clinicaltrials.gov/. Accessed 15 Feb 2017.

Mangan EK, Parrino J, Wu R, et al. Pharmacodynamic effect and safety of single-dose administration of subcutaneous sarilumab or intravenous tocilizumab in patients with rheumatoid arthritis [abstract no. APL16-0768]. Int J Rheum Dis. 2016;19(Suppl 2):196.

10.

Boyapati A, Msihid J, Fiore S, et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016;18(1):225.CrossRefPubMedPubMedCentral

11.

Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73:1626–34.CrossRefPubMed

12.

Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–37.CrossRefPubMed

13.

Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198.CrossRefPubMedPubMedCentral

14.

van der Heijde D, Fan C, van Hoogstraten H, et al. Consistency of radiographic responses with sarilumab plus methotrexate across subpopulations of patients with rheumatoid arthritis in a phase 3 study [abstract no. SAT0058]. Ann Rheum Dis. 2016;75(Suppl 2):685.

15.

Fleischmann R, Mangan EK, van Adelsberg J, et al. Onset of action of sarilumab in patients with rheumatoid arthritis in 2 phase 3 studies [abstract no. SAT0180]. Ann Rheum Dis. 2016;75(Suppl 2):733.CrossRef

16.

Strand V, Chen C, Mahajan P, et al. Early onset of benefit by patient-reported outcomes (PROs) with sarilumab treatment in RA [abstract no. AB0251]. Ann Rheum Dis. 2016;75(Suppl 2):984–5.

17.

Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active RA and inadequate response or intolerance to tumour necrosis factor inhibitors. Arthritis Rheumatol. 2016;69(2):277–90.CrossRef

18.

Strand V, Mahajan P, Chen C, et al. Benefit of sarilumab with csDMARDs on patient productivity in work, household work and family, social, leisure activities in TNF-IR RA patients [abstract no. AB0252]. Ann Rheum Dis. 2016;75(Suppl 2):985.

19.

Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2016-210310.

20.

Genovese MC, Fay J, Parrino J, et al. Sarilumab dose reduction to manage laboratory abnormalities in an open-label extension study in RA patients [abstract no. FRI0228]. Ann Rheum Dis. 2016;75(Suppl 2):515–6.

21.

Fleischmann R, Genovese MC, van Adelsberg J, et al. Pooled safety and efficacy of sarilumab in rheumatoid arthritis patients 65 years of age and older [abstract no. 1605]. Arthritis Rheumatol. 2016;68(Suppl 10).

22.

Sanofi, Regeneron Pharmaceuticals. Non-infectious uveitis: NCT01900431. 2017. http://clinicaltrials.gov/. Accessed 15 Feb 2017.

Titel: Sarilumab: First Global Approval
verfasst von: Lesley J. Scott
Publikationsdatum: 01.04.2017
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 6/2017
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-017-0724-2

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Triazole Resistance in Aspergillus Species: An Emerging Problem

Baricitinib: First Global Approval

Options for Treating Pain in Cancer Patients with Dysphagia

Diagnosis and Treatment of Non-24-h Sleep–Wake Disorder in the Blind

Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy

Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators